Berlin JD, et al. - Researchers performed this work to determine toxicity of two treatment arms, A (cetuximab) and B (bevacizumab), when combined with gemcitabine, and chemoradiation in patients with completely resected pancreatic carcinoma. Secondarily, they assessed overall survival and disease-free survival. With manageable toxicities, both treatments were tolerable. The treatments were safe enough to indicate a phase III trial.